CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
Combination of a novel growth hormone releasing hormone Antagonist JMR 132 and Tamoxifen enhances the inhibitory effects on growth of ZR 75 and T47D estrogen dependent human breast cancer cells in vitro and in vivo
DOI 10.1055/s-0029-1225201
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Buchholz, AV Schally, A Krishan, A Papadia, O Ortmann, S Seitz
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe06/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Tamoxifen is the oldest selective estrogen receptor modulator (SERM) developed to antagonize the estrogen receptor function on human breast cancer cells. JMR 132 is a novel GHRH Antagonist proven to be potent inhibitor of tumor growth in estrogen receptor negative human breast cancer cell lines. A combination of both substances could induce a more potent growth inhibition, as compared to the single drugs…
Zitieren
Zitierempfehlung
S Buchholz, AV Schally, A Krishan, A Papadia, O Ortmann, S Seitz (2009) Combination of a novel growth hormone releasing hormone Antagonist JMR 132 and Tamoxifen enhances the inhibitory effects on growth of ZR 75 and T47D estrogen dependent human breast cancer cells in vitro and in vivo. Geburtshilfe und Frauenheilkunde (06). https://doi.org/10.1055/s-0029-1225201
Mit CareLit weiterarbeiten